2 published verifications about High-Sensitivity C-Reactive Protein High-Sensitivity C-Reactive Protein ×
“Among patients 12 months after ST-elevation myocardial infarction, those with high-sensitivity C-reactive protein levels greater than 26.4 mg/L had a 12% rate of major adverse cardiovascular events, compared with a 4% rate among those with high-sensitivity C-reactive protein levels at or below 26.4 mg/L.”
The quoted 12% versus 4% event rates are supported by a 2024 peer-reviewed STEMI study. However, those numbers came from a selected cohort followed for about 12 months, and the 26.4 mg/L threshold was the study’s median hs-CRP level, not a broadly accepted universal cutoff. The data are accurate, but the wording is slightly broader than the underlying evidence.
“A 2025 study published in JACC: Advances of 456 patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention reported that the odds of intramyocardial hemorrhage increased by 95% for every 1 mg/L increase in high-sensitivity C-reactive protein measured at 48 hours (odds ratio 1.95; 95% CI 1.30–2.93).”
The study appears to have reported the cited cohort, setting, and odds ratio, and the claim captures the main association accurately. The caveat is that the paper, as described, does not explicitly confirm that the OR 1.95 should be read as “per 1 mg/L increase” or that this exact estimate is the only model reported. The numerical interpretation is therefore plausible but not fully nailed down from the cited text alone.